Erwan Mortier

Nantes, 44000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1.

Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1.

Journal: Science signaling

Published: September 16, 2025

Identification of Hepatic-like EPO as a Cause of Polycythemia.

Identification of Hepatic-like EPO as a Cause of Polycythemia.

Journal: The New England journal of medicine

Published: April 30, 2025

Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.

Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.

Journal: Molecular therapy. Oncology

Published: March 14, 2025

New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma.

New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma.

Journal: Journal for immunotherapy of cancer

Published: February 18, 2025

A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.

A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.

Journal: Cell reports. Medicine

Published: August 22, 2024

Full-length and N-terminally truncated recombinant interleukin-38 variants are similarly inefficient in antagonizing interleukin-36 and interleukin-1 receptors.

Full-length and N-terminally truncated recombinant interleukin-38 variants are similarly inefficient in antagonizing interleukin-36 and interleukin-1 receptors.

Journal: Cell communication and signaling : CCS

Published: July 25, 2024

Biology of GD2 ganglioside: implications for cancer immunotherapy.

Biology of GD2 ganglioside: implications for cancer immunotherapy.

Journal: Frontiers in pharmacology

Published: June 29, 2023

Editorial: Modulating cytokines as treatment for autoimmune diseases and cancer: volume II.

Editorial: Modulating cytokines as treatment for autoimmune diseases and cancer: volume II.

Journal: Frontiers in immunology

Published: May 19, 2023

The roles of different forms of IL-15 in human melanoma progression.

The roles of different forms of IL-15 in human melanoma progression.

Journal: Frontiers in immunology

Published: March 10, 2023

Counteracting Interleukin-15 to Elucidate Its Modes of Action in Physiology and Pathology.

Counteracting Interleukin-15 to Elucidate Its Modes of Action in Physiology and Pathology.

Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research

Published: January 18, 2023

Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation.

Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation.

Journal: Frontiers in immunology

Published: February 28, 2022

Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein.

Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein.

Journal: Bioorganic & medicinal chemistry

Published: January 20, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026